Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of Tuberculosis

New regimens based on two or more novel agents are sought to shorten or simplify treatment of tuberculosis (TB). Pretomanid (PMD) is a nitroimidazole in phase 3 trials that has significant bactericidal activity alone and in combination with bedaquiline (BDQ) and/or pyrazinamide (PZA). We previously...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Antimicrob Agents Chemother
Glavni autori: Tasneen, Rokeya, Betoudji, Fabrice, Tyagi, Sandeep, Li, Si-Yang, Williams, Kathy, Converse, Paul J., Dartois, Véronique, Yang, Tian, Mendel, Carl M., Mdluli, Khisimuzi E., Nuermberger, Eric L.
Format: Artigo
Jezik:Inglês
Izdano: American Society for Microbiology 2015
Teme:
Experimental Therapeutics
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4704221/
https://ncbi.nlm.nih.gov/pubmed/26503656
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01691-15
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items